What skepticism is there regarding advanced atopic dermatitis treatment options?

News
Video

Peter Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine in Chicago, Illinois, discusses the 2023 Society for Pediatric Dermatology Meeting held in Asheville, North Carolina, and what pearls to consider following the atopic dermatitis panel he took part in.

Transcript (edited for clarity):

Contemporary Pediatrics®: What value did different aspects of today's atopic dermatitis panel present to pediatric dermatologists from across the country?

Peter Lio, MD: We had a really neat session on atopic dermatitis. We had 3 different opinions and 3 different panelists who took different pathways, if you will. One of them was talking about all of the new and exciting treatments, of which there is a ton. So Dr. [Amy] Paller really broke down a lot of the new topicals and systemics. And the fact that we now have a biologic agent down to patients 6 months of age, which is pretty amazing. Then Dr. Steve Feldman from Wake Forest talked all about adherence to our regimens, and just how important that is and how it's really our problem. If we're not getting our patients do it here, it means we don't have the proper buy in. So I thought that was fascinating. And thinking about how we can do better on that. That's an area we have to improve.

I talked a little bit about integrative approaches and thinking about how can we use some of the non-traditional techniques and treatments to help, I think, improve the patient experience overall, and to really kind of meet some of the unmet needs in areas where we might never get medications because they're gentler and more supportive type treatments. So I talked about black tea compresses. I talked about topical indigo naturalis. I even talked talked a little bit about how oral hemp seed oil was shown to help reduce some of the symptoms of atopic dermatitis. And really, it's in the spirit of finding things to help meet our patients part of the way.

Contemporary Pediatrics: What skepticism do parents of pediatric patients address as new treatment options emerge?

Lio: Yes, you know, it's funny, I think we see both extremes. We see the whole gamut. But the 2 extremes are: I have families who sort of don't want to use anything that's not natural. You know, "I don't want chemicals, I don't want drugs, it's too much stuff." And I'm sympathetic to a certain degree. I mean, we live in this weird modern world where almost nothing we do is close to nature. On the other extreme, sometimes we have this pressure to start using some of these better things. People don't even want to start with the basics. They just get it better, quick fix. Let's go. And that was one of the really good questions that was brought up at the end, "Do you feel comfortable using some of these more powerful treatments and babies? Do we always need it?"

So, I think there is this tension and everything in between. So I think we're really trying to reassess each situation each individual make sure have we done all the right things? Have we gone through with good education? Are we sure it's the right diagnosis? Are we sure they're comfortable using the simplest and safest treatments? And did those really fail us? And if so, if they're still having trouble, and it's still causing a lot of, you know, because we know this can cause a huge burden of disease, a lot of impact on quality of life, and not just for the patient. But for the whole family. Sometimes the whole family comes in, everybody has bags under their eyes, everybody sobbing. I feel it, my mood just drops. And the moment I walk in there, I'm like, "Oh, my goodness, you guys are really, really suffering." And so in that case, I think it's much clearer that we need to do something bigger. We need to make a change. But there are other cases where I think sometimes I've even maybe been too aggressive. And patients say, "You know, do we need to do that yet? Let's hold your horses." So we're always trying to find that equanimity to balance it correctly. And that is the art, I think of medicine.

Contemporary Pediatrics: What are additional opportunities for research in the management of atopic dermatitis?

Lio: There are so many unmet needs, and so many questions. And in fact, I think that we're in this phase, I like to call it the virtuous cycle of drug development. We get a medicine and that helps us learn a little bit more about the condition atopic dermatitis here, which then allows for better treatments, which then allows for refinement in our understanding, and so on. So we're in this virtuous cycle. Now, we still have some of the basic questions that we don't understand. We still don't really know what causes it. Right? If you asked me point blank, what is the cause? It I'll kind of tell you a few different things that we think are related to it. We think there are some genes that are associated with it. There's some environmental things, but I can't really give you especially for an individual patient. Why? So that's huge. We're also still trying to understand the role of the microbiome. We're trying to understand, can we prevent it in people that we think are at higher risk? Because we know there's certainly a genetic component and a family component. Can we do that? Can we find other ways to help with the mind body piece? The behavioral aspect?

There's a huge, huge unmet need there because a lot of my patients will tell me, even if they're not having a flare up, stress can induce one. So what does that tell us? That there's more to this than just bacteria? There's more to this than just dry skin? There's more to this than just inflammation? This is a complex disease with many, many different facets.

Contemporary Pediatrics: What should clinicians in all specialties keep in mind about atopic dermatitis and continued research about the condition?

Lio: I think this is a problem for everybody. Even for non specialists. I think atopic dermatitis is so common, you know, there are estimates as high as 20% of children being affected by this. So I think pediatrics, family practice, all throughout medicine, we're seeing this and it affects of course, the family. So maybe you're seeing an adult patient for internal medicine, but they're exhausted and then you ask what's going on? Our baby has terrible eczema. So these are a drain for so many people and a drain on society. And I think that's why it's one of those things that we can really rally together. I want all the good ideas. I want all the help I can get. I have no ego when it comes to this because I keep learning I keep getting schooled on it and that's what I want. It's a bad day when I don't learn something new about this really tough to treat disease.

This video was initially published by our sister publication, Dermatology Times®.

Related Videos
Lawrence Eichenfield, MD
Lawrence Eichenfield, MD | Image credit: KOL provided
FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and older | Image Credit: bankrx - Image Credit: bankrx - stock.adobe.com.
Related Content
© 2024 MJH Life Sciences

All rights reserved.